Related Experiment Video
Updated: Mar 14, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Palliative and End-of-Life Care in Myelodysplastic Syndromes
Myles Nickolich1, Areej El-Jawahri2, Thomas W LeBlanc3,4
1Divisions of Hematology, Medical Oncology, and Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
Abstract:
A growing literature demonstrates that MDS is associated with significant impairments in overall quality of life. Given the poor prognosis for many patients with MDS, and the considerable morbidities associated with this disease, there is a critical need to address palliative and end-of-life care needs in this population. However, palliative and end-of-life care issues are under-represented in the MDS literature. In this article, we highlight a growing body of literature that demonstrates unmet palliative and end-of-life care needs in hematologic malignancies, including MDS, and highlight opportunities for further research and quality improvement initiatives to address unmet needs in MDS care.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Continuing Care
Cardiomyopathy II: Dilated Cardiomyopathy
Chronic Pancreatitis II: Collaborative Care
Assessment:
Peripheral Artery Disease III: Interprofessional Care
Peritoneal Dialysis III: Nursing Management

